Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Johnson & Johnson: Is It Too Late?
- Ryan Savitz submits: The markets cannot seem to catch a breather, find a glimpse of hope, or even come close to ending the day flat. Even Healthcare has been getting beaten up recently. Recessionary proof? I do not feel anything is recessionary proof in this current environment. The Healthcare Select...
- External links 2008-10-15
- Teva: The Generics Giant Shines
- Ryan Savitz submits: With another tough day in the market following the Presidential Election, the world’s largest generic drug maker topped 3rd Quarter net profit forecasts. Teva TEVA headquarted in Israel, develops, manufactures, and markets generic and human pharmaceuticals. They also participate in the formation of active pharmaceuticals, or APIs, in North...
- External links 2008-11-10
- Johnson & Johnson: Lowered Guidance Tamped Down Q4 Earnings Excitement
- Ryan Savitz submits: Johnson & Johnson JNJ reported fourth quarter earnings on Tuesday beating estimates and making many analysts, who were once quite skeptical about the company, somewhat excited. However, shortly after the net income and EPS numbers came out, JNJ lowered guidance. This understandably came during tough economic...
- External links 2009-01-22
- Gilead Sciences: Great Quarter, Strong Anti-Viral Franchise Make It a Buy
- Ryan Savitz submits: Gilead Sciences GILD pleased its investors yet again with another quarter of great earnings. The biotechnology company from Foster City, California has truly proven to investors that they can withstand the tough economic conditions across the globe, even offering high priced drugs. More importantly, the company has...
- External links 2009-02-02
- Abbott Labs: Powerful Company with a Bright Future
- Ryan Savitz submits: 2008 was quite an interesting and exciting year for the Healthcare sector. Each sub-sector was struck with their own disruptions and it caused industry wide job cuts and strategic maneuvers. The Obama administration has come in and new legislation will be passed most likely hurting Biotechnology,...
- External links 2009-02-22
- Teva: What's Next for the 'Generic Giant'?
- Ryan Savitz submits: TEVA, the “Generic Giant,” as I referred to it back in November when I recapped its quarterly earnings, continues to outshine and outclass its peers on pretty much every level. Since I have followed healthcare equities for quite some time now and kept my focus solely on...
- External links 2009-03-23
- Abbott, Teva: Tough Enough to Withstand Rocky Market
- Ryan Savitz submits: The recent volatility from the Healthcare sector has left many investors wary about where to place their money. General market swings aside, M&A activity and legislative developments have intensified the uncertainty in the sector, but have also led to many investment opportunities. M&A has been very...
- External links 2009-03-31
Additional Resources
- CROs: The 'Big Pharma Effect'
- Ryan Savitz submits: I have not been the first nor will I be the last to point out the troubles of Big Pharma; however, how can you as an investor take advantage of the weak sub-sector and transfer your investments to another attractive area of Healthcare that will be reaping...
- External links 2008-08-28
- << Previous
- page 1 of 1
- Next >>
Presented by American Express